Transenterix Inc (NYSE:TRXC) had its target price boosted by Stifel Nicolaus from $3.75 to $4.00 in a research report released on Tuesday. They currently have a buy rating on the medical instruments supplier’s stock.
Transenterix (TRXC) traded down 5.41% on Tuesday, reaching $2.80. 3,776,272 shares of the company traded hands. The company’s market capitalization is $415.90 million. The stock has a 50-day moving average of $1.98 and a 200 day moving average of $1.04. Transenterix has a 52-week low of $0.45 and a 52-week high of $5.00.
COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/01/transenterix-inc-trxc-given-new-4-00-price-target-at-stifel-nicolaus.html.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
What are top analysts saying about Transenterix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Transenterix Inc and related companies.